Compare Mesoblast Limited (MESO) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sibanye Stillwater Ltd — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: Sibanye Stillwater Ltd is far larger — about 3.9× Mesoblast Limited's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Sibanye Stillwater Ltd for 51 Days on average.
| MESO | SBSW | |
|---|---|---|
Market Cap | $1.75B | $6.88B |
Volume | 239,027 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $20.96 | $21.12 |
52-Week Low | $13.19 | $8.00 |
Typical Hold Time | 15 Days | 51 Days |
Enterprise Value | $1.83B | $7.78B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
SBSW trades at $9.91, up 2.38% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% EBITDA increase, driving positive sentiment.
The outlook is mixed: analyst consensus is a 'Buy' with a $14.25 price target, implying 44% upside, supported by operational improvements and commodity price strength. Risks include volatile earnings, high debt levels, and exposure to commodity cycles. Upside hinges on sustained execution of the growth roadmap and cost discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
